Tirzepatide-ROU is a cutting-edge therapeutic agent designed to mimic the actions of both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). This dual incretin mimetic exerts its effects by activating to the GLP-1 and GIP receptors, thereby boosting insulin secretion in a glucose-responsive manner. The resulting